4-methoxy-2,3-dimethylcinnamic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-methoxy-2,3-dimethylcinnamic acid
• 英文别名: 4-Methoxy-2,3-dimethylzimtsaeure；(E)-3-(4-Methoxy-2,3-dimethylphenyl)prop-2-enoic acid
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: NLBZFUNXIYHKBV-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methoxy-2,3-dimethylcinnamic acid 在 sodium hydroxide 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (E)-8-(4-Methoxy-2,3-dimethylstyryl)-7-methyl-1,3-dipropylxanthine
  参考文献：
  名称：

  Adenosine A2A antagonists with potent anti-cataleptic activity

  摘要：

  Structure-activity relationships of 8-styrylxanthines for in vivo adenosine A(2A) antagonism were explored. Diethyl substitution both at the 1- and 3-posit;on was found to dramatically potentiate the anti-cataleptic activity. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00440-x

文献信息

• Therapeutic agent for Parkinson's disease
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05484920A1

  公开（公告）日：1996-01-16

  Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.

  治疗帕金森病的药剂，其活性成分是一种黄嘌呤衍生物或其药物可接受的盐。该黄嘌呤衍生物的化学公式如下：##STR1## 其中，R.sup.1、R.sup.2和R.sup.3独立地代表氢、低级烷基、低级烯基或低级炔基；R.sup.4代表环烷基、--(CH.sub.2).sub.n --R.sup.5（其中R.sup.5代表取代或未取代的芳基或取代或未取代的杂环族；n是0到4之间的整数），或##STR2## 其中，Y.sup.1和Y.sup.2独立地代表氢、卤素或低级烷基；Z代表取代或未取代的芳基，##STR3## 其中，R.sup.6代表氢、羟基、低级烷基、低级烷氧基、卤素、硝基或氨基；m代表1到4之间的整数，或取代或未取代的杂环族；X.sup.1和X.sup.2独立地代表氧或硫。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR GPR120 ET LEURS UTILISATIONS
  申请人：METABOLEX INC

  公开号：WO2011159297A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE RÉCEPTEURS GPR 120 ET LEURS APPLICATIONS
  申请人：METABOLEX INC

  公开号：WO2010080537A1

  公开（公告）日：2010-07-15

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• GPR120 RECEPTOR AGONISTS AND USES THEREOF
  申请人：Shi Dong Fang

  公开号：US20110313003A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  提供了GPR120激动剂。这些化合物对于治疗代谢性疾病非常有用，包括II型糖尿病和与血糖控制不佳有关的疾病。
• Therapeutic agents for use in the treatment of parkinson's disease
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0565377A1

  公开（公告）日：1993-10-13

  Disclosed are therapeutic agents for use in the treatment of Parkinson's disease, such agents being xanthine derivatives of the Formula (I) and their pharmaceutical acceptable salts : where R1, R2 and R3 are each H, C1-C6 alkyl or allyl ; and R4 is cycloalkyl of 3 to 8 carbon atoms, a -(CH2)n-R5 group where n is an cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R5 group where n is an integer of from 0-4 and R5 is an aryl group of 6 to 10 carbon atoms or a heterocyclic group, such aryl or heterocyclic group optionally being substituted by up to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino ; or a group, where Y1 and Y2 are each H or CH3 and Z is a substituted or unsubstituted aryl or heterocyclic group as defined under R5.

  本发明揭示了治疗帕金森病的治疗剂，该治疗剂为公式（I）的黄嘌呤衍生物及其药物可接受的盐：其中，R1、R2和R3分别为H、C1-C6烷基或丙烯基；而R4为3至8个碳原子的环烷基，-(CH2)n-R5基团，其中n为3至8个碳原子的环烷基，-(CH2)n-R5基团，其中n为0-4的整数，而R5为6至10个碳原子的芳基基团或杂环基团，所述芳基或杂环基团可选地被选自C1-C6烷基，羟基，C1-C6烷氧基，卤素，硝基和氨基的最多3个取代基所取代；或Y1和Y2分别为H或CH3，而Z为根据R5所定义的取代或未取代的芳基或杂环基团的一个基团。